Investment gains to advance Acuvax's vaccine ambitions
This article was originally published in Scrip
Executive Summary
Acuvax has divested to an unnamed European company its 10% holding in the private German oncology firm RESprotect. The Australian venture retains an interest in RESprotect's lead project, RP101 (BVdU), which is being developed by SciClone Pharmaceuticals.